title: Mechanism of Anti-α-Synuclein Immunotherapy.
abstract: Immunization therapy targeting α-synuclein has emerged as a promising approach for Parkinson's disease and perhaps for other synucleinopathies. Several antibodies have shown therapeutic effects in mouse models of synucleinopathies and have alleviated the pathological and behavioral phenotypes of these mice. The mechanisms through which the immunization therapy works were initially puzzling, especially given that α-synuclein is a typical cytosolic protein. Recent studies, however, suggested that extracellular α-synuclein is an important pathogenic entity, and hence, a target for immunotherapy. Here, we review the literature describing immunization therapy for synucleinopathies in mouse models and provide current thoughts on the potential mechanisms underlying the therapeutic effects of α-synuclein immunotherapy.
authors.affiliation: Department of Biomedical Sciences, Neuroscience Research Institute, Seoul National University College of Medicine, Seoul, Korea.
authors.forename: Jun Sung
authors.initials: JS
authors.lastname: Lee
authors.affiliation: Department of Biomedical Sciences, Neuroscience Research Institute, Seoul National University College of Medicine, Seoul, Korea.
authors.forename: Seung-Jae
authors.initials: SJ
authors.lastname: Lee
keywords: Aggregate transmission; Immunotherapy; Microglia activation; Synucleinopathy; α-synuclein
references.citation: PLoS One. 2011;6(10):e27230
references.pmid: 22073131
references.citation: Int J Biochem Cell Biol. 2008;40(9):1835-49
references.pmid: 18291704
references.citation: Neuron. 2005 Jun 16;46(6):857-68
references.pmid: 15953415
references.citation: J Neurochem. 2013 May;125(4):487-90
references.pmid: 23448303
references.citation: Sci Transl Med. 2011 May 25;3(84):84ra43
references.pmid: 21613622
references.citation: Nat Rev Neurosci. 2013 Jan;14 (1):38-48
references.pmid: 23254192
references.citation: Parkinsons Dis. 2011 Feb 17;2011:708404
references.pmid: 21403906
references.citation: NeuroRx. 2004 Jan;1(1):139-54
references.pmid: 15717014
references.citation: PLoS One. 2011 Apr 29;6(4):e19338
references.pmid: 21559417
references.citation: Brain. 2013 Apr;136(Pt 4):1128-38
references.pmid: 23466394
references.citation: J Biol Chem. 2013 Jun 14;288(24):17313-35
references.pmid: 23629650
references.citation: Nat Genet. 1998 Feb;18(2):106-8
references.pmid: 9462735
references.citation: J Neurochem. 2010 Jun;113(5):1263-74
references.pmid: 20345754
references.citation: J Neurosci. 2010 May 19;30(20):6838-51
references.pmid: 20484626
references.citation: Nat Commun. 2014 Aug 26;5:4755
references.pmid: 25156829
references.citation: Nat Genet. 2009 Dec;41(12):1308-12
references.pmid: 19915575
references.citation: Lancet. 2004 Sep 25-Oct 1;364(9440):1169-71
references.pmid: 15451225
references.citation: J Neurosci. 2005 Jun 22;25(25):6016-24
references.pmid: 15976091
references.citation: FASEB J. 2011 Jan;25(1):326-36
references.pmid: 20876215
references.citation: J Neurochem. 2012 Jan;120 Suppl 1:186-93
references.pmid: 21883222
references.citation: Science. 1997 Jun 27;276(5321):2045-7
references.pmid: 9197268
references.citation: Exp Mol Med. 2011 Apr 30;43(4):216-22
references.pmid: 21415592
references.citation: Science. 2003 Oct 31;302(5646):841
references.pmid: 14593171
references.citation: Ann Neurol. 2013 Apr;73(4):459-71
references.pmid: 23526723
references.citation: J Clin Invest. 2011 Feb;121(2):715-25
references.pmid: 21245577
references.citation: Neuron. 1995 Feb;14(2):467-75
references.pmid: 7857654
references.citation: Immunotherapy. 2012 Feb;4(2):213-38
references.pmid: 22339463
references.citation: Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):13010-5
references.pmid: 19651612
references.citation: Nat Rev Neurol. 2014 Feb;10(2):92-8
references.pmid: 24468877
references.citation: Biochem Biophys Res Commun. 2008 Aug 1;372(3):423-8
references.pmid: 18492487
references.citation: Ann Neurol. 2008 Jun;63(6):743-50
references.pmid: 18571778
references.citation: J Biol Chem. 2010 Mar 19;285(12):9262-72
references.pmid: 20071342
references.citation: Ann Neurol. 2004 Feb;55(2):164-73
references.pmid: 14755719
references.citation: Exp Mol Med. 2013 May 10;45:e22
references.pmid: 23661100
references.citation: Lancet. 2004 Sep 25-Oct 1;364(9440):1167-9
references.pmid: 15451224
references.citation: Science. 2012 Nov 16;338(6109):949-53
references.pmid: 23161999
references.citation: J Neuropathol Exp Neurol. 1996 Mar;55(3):259-72
references.pmid: 8786384
references.citation: Neuron. 2011 Oct 6;72(1):57-71
references.pmid: 21982369
references.citation: Mov Disord. 2013 Jun;28(6):811-3
references.pmid: 23457019
references.citation: J Neurochem. 2010 Jun;113(5):1188-99
references.pmid: 20345765
references.citation: Cell Rep. 2014 Jun 26;7(6):2054-65
references.pmid: 24931606
references.citation: Neurology. 2008 May 13;70(20):1916-25
references.pmid: 18474848
references.citation: J Neurosci. 2012 Sep 26;32(39):13454-69
references.pmid: 23015436
references.citation: Antioxid Redox Signal. 2013 Mar 1;18(7):770-83
references.pmid: 22867050
references.citation: Exp Mol Med. 2014 Apr 18;46:e91
references.pmid: 24743837
references.citation: Nat Commun. 2013;4:1562
references.pmid: 23463005
references.citation: Nat Rev Neurol. 2010 Feb;6(2):108-19
references.pmid: 20140000
references.citation: Nat Genet. 2009 Dec;41(12 ):1303-7
references.pmid: 19915576